KB
EXAS

Kimelman & Baird’s Exact Sciences EXAS Stock Holding History

Kimelman & Baird’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,997
Closed -$203K – 267
2025
Q4 		$203K Hold
1,997
– – 0.02% 112
2025
Q3 		$109K Hold
1,997
– – 0.01% 142
2025
Q2 		$106K Hold
1,997
– – 0.01% 143
2025
Q1 		$86.5K Hold
1,997
– – 0.01% 155
2024
Q4 		$112K Hold
1,997
– – 0.01% 148
2024
Q3 		$136K Hold
1,997
– – 0.01% 141
2024
Q2 		$84.4K Buy
+1,997
New +$110K 0.01% 161
2021
Q2 		$517K Buy
+4,159
New +$496K 0.05% 80

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Kimelman & Baird's EXAS Position: Q1 2026 in Review

Kimelman & Baird sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 1,997 shares — an estimated $203K sold.

Kimelman & Baird first reported a position in EXAS in Q2 2021 and held it in 8 quarters. The position peaked at $517K in Q2 2021. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Kimelman & Baird reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Kimelman & Baird sold 1,997 Exact Sciences shares in Q1 2026, an estimated $203K.
  • Kimelman & Baird first reported a position in Exact Sciences in Q2 2021 and held it in 8 quarters.
  • Kimelman & Baird's Exact Sciences position peaked at $517K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Kimelman & Baird's 13F filing for Q1 2026, filed 13 May 2026.